WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that new findings from its Phase 2a trial of ATI-2138, an investigational oral therapy for moderate-to-severe atopic dermatitis, will be featured in a late-breaking oral presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris.
The presentation, scheduled for September 18, will be delivered by Dr. Jessica Beaziz-Tordjman of Mount Sinai’s Department of Dermatology. It will highlight molecular and clinical data from an open-label study evaluating ATI-2138, a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3).
ATI-2138 is designed to target immune pathways that regulate T cell activation and cytokine signaling, mechanisms central to inflammatory and autoimmune diseases. Preclinical models, early human safety studies, and initial Phase 2a results have shown promise, supporting further development of the drug in atopic dermatitis and other immune-mediated conditions.
Aclaris, a clinical-stage biopharmaceutical company, is advancing a pipeline of therapies aimed at addressing unmet needs in immuno-inflammatory diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.